Resurgence of Interest in the Role of HDL / Modulating CETP to Reduce Cardiovascular Risk / dal-VESSEL, dal-PLAQUE & DEFINE Trials

Authors

  • Hector Anninos Evagelismos Hospital, Athens
  • Antonis S Manolis Evagelismos General Hospital, Athens

DOI:

https://doi.org/10.2015/hc.v7i1%20Sup.500

Keywords:

high-density lipoprotein, cardiovascular risk, reverse cholesterol transport, atherosclerosis, dalcetrapid, anacetrapid

Abstract

The significance of HDL concentration in assessing cardiovascular risk has been recognized over 20 years ago by the Framingham study and it has been subsequently confirmed by other studies and meta-analyses. However, LDL cholesterol has been assigned the cardinal role in cardiovascular (CV) risk management because of its clear etiopathogenic correlation with CV outcome and the efficacy of the drugs used to manipulate its levels in order to change patient prognosis. It is rather recently that HDL has gained the scientific interest once again, with the development of novel agents exhibiting a remarkable ability in raising HDL levels. In this article we comment on the re-emerging role of HDL manipulation with regard to the new CETP inhibitors, under the light of the recent data obtained from large trials assessing their efficacy and safety.

Author Biography

Antonis S Manolis, Evagelismos General Hospital, Athens

Specialty: Cardiology

Downloads

Published

2012-04-11

Issue

Section

ATHENS CARDIOLOGY UPDATE 2012